NEW YORK, March 11, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Orexigen Therapeutics, Inc. ("Orexigen" or the "Company") (NASDAQ: OREX), concerning whether the board has breached its fiduciary duties to shareholders.
On March 5, 2015, an article was published in Forbes titled "Top FDA Official Says Orexigen Study Result 'Unreliable,' 'Misleading.'" The article stated that the post-marketing clinical trial program for Orexigen's obesity drug, Contrave, was likely "unreliable," "misleading," and "false." According to the article, the Company could be forced withdraw Contrave from the market.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Orexigen shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP